非布司他治疗原发性痛风合并轻中度肾功能不全的临床疗效

Clinical Efficacy of Febuxostat in the Treatment of Primary Gout with Mild to Moderate Renal Insufficiency

目的探究非布司他治疗原发性痛风合并轻中度肾功能不全的临床疗效。方法选取我院2017年1月至2018年8月期间收治的64例原发性痛风合并轻中度肾功能不全患者随机均分成实验组、对照组(各32例)。对照组行别嘌呤治疗,实验组行非布司他治疗。对比两组患者的血尿酸、肾功能变化、痛风再发作次数及不良反应情况等。结果实验组治疗3个月时的血尿酸水平、并发症发生率低于对照组(P<0.05),差异有统计学意义。两组患者肾功能、痛风再发作次数差异不明显(P>0.05),差异无统计学意义。结论给予原发性痛风合并轻中度肾功能不全患者非布司他治疗可有效缓解患者病情,值得临床大力推广及应用。

Objective To explore the clinical efficacy of febuxostat in the treatment of primary gout with mild to moderate renal insufficiency. Methods Sixty-four patients with primary gout complicated with mild to moderate renal insufficiency admitted to our hospital from January 2017 to August 2018 were randomly divided into experimental group and control group(32 cases each). The control group was treated with sputum and the experimental group was treated with febuxostat. The blood uric acid, renal function changes, the number of recurrent episodes and adverse reactions were compared between the two groups. Results The blood uric acid level and complication rate in the experimental group were lower than those in the control group at 3 months(P<0.05), and the difference was statistically significant. There was no significant difference in the number of renal function and gout recurrence between the two groups(P>0.05), and the difference was not statistically significant. Conclusion The administration of febuxostat in patients with primary gout combined with mild to moderate renal insufficiency can effectively alleviate the patient’s condition and is worthy of clinical promotion and application.